Cy5-Paclitaxel bromide

Operating Instructions
(The following is a recommended experimental protocol for guidance only; adjust according to actual requirements)

1. Stock Solution Preparation
1.1 Solvent: For most dyes, organic solvents are commonly used for dissolution, such as anhydrous DMSO.
1.2 Concentration Recommendation: It is generally recommended to prepare a high-concentration stock solution of 1-10 mM.

2. Working Solution Preparation
2.1 Diluent: Cell culture medium.
2.2 Working Concentrations: 50 nM, 100 nM, 200 nM, 400 nM.
2.3 Notes: Adjust the working solution concentration as needed; prepare and use immediately.

3. Staining Procedure
3.1 Sample Type: Adherent breast cancer cells (MDA-MB-231)
3.2 Incubation Conditions: Incubate at 37°C for 48 h or 72 h in a humidified environment containing 5% CO₂.
3.3 Washing Step: No washing step is specified in this experiment.

4. Control Group Setup
4.1 Blank Control: Unconjugated RNA pyramid nanoparticles (at the same test concentration as Cy5-Paclitaxel bromide-conjugated nanoparticles).

5. Detection and Analysis
5.1 Instruments: Fluorescence imaging system for Cy5 detection; microplate reader for absorbance detection.
5.2 Result Analysis:
5.2.1 Fluorescence Intensity Change: After irradiation with 365 nm ultraviolet light, the fluorescence intensity of Cy5 decreases.
5.2.2 Cell Viability: Compared with unirradiated samples and samples without photocleavable spacers, the Cy5-Paclitaxel bromide-conjugated RNA nanocages with photocleavable spacers show enhanced inhibitory effect on cell viability after ultraviolet irradiation.
5.2.3 Color Change: Cell viability is evaluated by detecting absorbance at 570 nm via MTT assay, where a decrease in absorbance corresponds to reduced cell viability.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.